UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000016273 |
|---|---|
| Receipt number | R000018879 |
| Scientific Title | Rheumatoid Arthritis with Orencia Trial Toward Sjogren's syndrome Endocrinopathy (ROSE II Trial) |
| Date of disclosure of the study information | 2015/01/20 |
| Last modified on | 2022/07/27 13:14:25 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Rheumatoid Arthritis with Orencia Trial Toward Sjogren's syndrome Endocrinopathy (ROSE II Trial)
Acronym
Rheumatoid Arthritis with Orencia Trial Toward Sjogren's syndrome syndrome Endocrinopathy (ROSE II Trial)
Scientific Title
Rheumatoid Arthritis with Orencia Trial Toward Sjogren's syndrome Endocrinopathy (ROSE II Trial)
Scientific Title:Acronym
Rheumatoid Arthritis with Orencia Trial Toward Sjogren's syndrome syndrome Endocrinopathy (ROSE II Trial)
Region
| Japan |
Condition
Condition
Rheumatoid Arthritis complicated with Sjogren's syndrome
Classification by specialty
| Clinical immunology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Usefulness, including remission rate by SDAI, Saxon test, salivary gland image assessment, anti-SS-A/Ro antibody, anti-SS-B/La antibody, IgG, improvement of patient VAS, ESSDAI, ESSPRI, articular X-ray assessment, articular MRI assessment, articular ultrasonography, and the incidence of adverse reactions during 12 months of abatacept administration to patients with rheumatoid arthritis (RA) complicated with Sjogren's syndrome (SS) will be verified.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Assessment
Primary outcomes
The percentage of patients who achieved clinical remission by SDAI at 52 weeks
Key secondary outcomes
1) CRP, ESR, RF
2) Saxon's test
3) MRI of parotid glands
4) anti-SS-A/SS-B antibody, IgG
5) patients'VAS
6) Joint X-P
7) Joint MRI
8) Joint ultrasonography
9) ESSDAI
10) ESSPRI
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 75 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1) Patients aged 20 and more than 20 years old
2) Diagnosed with RA according to the American College of Rheumatology (ACR) 1987 or ACR/ European League Against Rheumatism (EULAR) 2010 criteria
3) Patients who correspond with eligible patients for treatments with abatacept according to the JCR guideline 2010, or who have SDAI>=11 or DAS28-ESR>=3.2 regarded as eligible patients by the attending physicians
4) Diagnosed with SS according to the Japanese Ministry of Health criteria for the diagnosis of SS 1999 and AECG criteria for SS 2002
5) Patients with subjective sicca symptoms
6) Patients who give a written informed consent to this study
Key exclusion criteria
1) Patients with contraindication for abatacept
2) Aged 75 and more than 75 years old
3) Patients with leukopenia (leukocyte count<=3000) and positive for B-D Glucan
4) Patients who are pregnant, nursing, want to get pregnant
5) Aged less than 20 years old
6) Patients who are treated with palliative therapies for dryness including cevimeline, anetholtritione, and pilocarpine within the last 4 weeks
7) Patients with severe liver or kidney diseases, severe hematological disorders
8) Patients with negative for both anti-SS-A and SS-B antibody and positive for anti-centromere antibody
9) Patients who are considered not suitable for this study by the attending physicians
Target sample size
81
Research contact person
Name of lead principal investigator
| 1st name | Isao |
| Middle name | |
| Last name | Matsumoto |
Organization
Department of Internal Medicine, Faculty of Medicine, University of Tsukuba
Division name
Division of Rheumatology
Zip code
305-8575
Address
1-1-1 Tennodai, Tsukuba-city, Ibaraki 305-8575, Japan
TEL
029-853-3186
ismatsu@md.tsukuba.ac.jp
Public contact
Name of contact person
| 1st name | Hiroto |
| Middle name | |
| Last name | Tsuboi |
Organization
Department of Internal Medicine, Faculty of Medicine, University of Tsukuba
Division name
Division of Rheumatology
Zip code
305-8575
Address
1-1-1 Tennodai, Tsukuba-city, Ibaraki 305-8575, Japan
TEL
029-853-3186
Homepage URL
Hiroto-Tsuboi@md.tsukuba.ac.jp
Sponsor or person
Institute
Department of Internal Medicine, Faculty of Medicine, University of Tsukuba
Institute
Department
Personal name
Funding Source
Organization
Bristol-Myers Squibb (BMS)
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
USA
Other related organizations
Co-sponsor
1) University of Occupational and Environmental Health
2) Nagasaki University
3) Hokkaido University
4) Kanazawa University
5) Keio University
6) Nihon University Itabashi Hospital
7) Juntendo University Hospital
8) Saitama Medical University
9) Kyoto University
10) National Hospital Organization Osaka Minami Medical Center
11) Hyogo College of Medicine
12) Kurashiki Medical Center
Name of secondary funder(s)
IRB Contact (For public release)
Organization
The local ethics committees of University of Tsukuba Hospital
Address
2-1-1 Amakubo, Tsukuba-city, Ibaraki 305-8576, Japan
Tel
029-853-3914
chiken@un.tsukuba.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
1）筑波大学（茨城県）
2）産業医科大学（福岡県）
3）長崎大学病院（長崎県）
4）北海道大学病院（北海道）
5）金沢大学附属病院（石川県）
6）慶應義塾大学病院（東京都）
7）日本大学医学部附属板橋病院（東京都）
8）順天堂大学医学部附属順天堂医院（東京都）
9）埼玉医科大学（埼玉県）
10）京都大学附属病院（京都府）
11）国立病院機構大阪南医療センター（大阪府）
12）兵庫医科大学病院（兵庫県）
13）倉敷成人病クリニック（岡山県）
1) University of Tsukuba (Ibaraki)
2) University of Occupational and Environmental Health (Fukuoka)
3) Nagasaki University (Nagasaki)
4) Hokkaido University (Hokkaido)
5) Kanazawa University (Ishikawa)
6) Keio University (Tokyo)
7) Nihon University Itabashi Hospital (Tokyo)
8) Juntendo University Hospital (Tokyo)
9) Saitama Medical University (Saitama)
10) Kyoto University (Kyoto)
11) National Hospital Organization Osaka Minami Medical Center (Osaka)
12) Hyogo College of Medicine (Hyogo)
13) Kurashiki Medical Center (Okayama)
Other administrative information
Date of disclosure of the study information
| 2015 | Year | 01 | Month | 20 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
Number of participants that the trial has enrolled
68
Results
Results date posted
Results Delayed
| Delay expected |
Results Delay Reason
Under preparation
Date of the first journal publication of results
| 2022 | Year | 02 | Month | 04 | Day |
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Main results already published
Date of protocol fixation
| 2014 | Year | 08 | Month | 04 | Day |
Date of IRB
| 2014 | Year | 08 | Month | 04 | Day |
Anticipated trial start date
| 2014 | Year | 08 | Month | 04 | Day |
Last follow-up date
| 2020 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
| 2021 | Year | 12 | Month | 31 | Day |
Date trial data considered complete
| 2021 | Year | 12 | Month | 31 | Day |
Date analysis concluded
| 2021 | Year | 12 | Month | 31 | Day |
Other
Other related information
1) The percentage of patients who achieved clinical remission by SDAI at 52 weeks
2) CRP, ESR, RF
3) Saxon's test
4) MRI of parotid glands
5) anti-SS-A/SS-B antibody, IgG
6) patients'VAS
7) Joint X-P
8) Joint MRI
9) Joint ultrasonography
10) ESSDAI
11) ESSPRI
Management information
Registered date
| 2015 | Year | 01 | Month | 20 | Day |
Last modified on
| 2022 | Year | 07 | Month | 27 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018879
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
